source
- SK Biopharma signs $795 million licensing deal with Biohaven for epilepsy therapy opakalimSK Biopharma has entered a licensing agreement with Biohaven Pharmaceuticals to acquire worldwide rights to the Kv7 ion channel activator opakalim (BHV-7000) for epilepsy. The deal provides an upf…
- With mRNA back in the spotlight, tRNA shows potential to treat genetic diseaseNew research coming out of the University of Toronto has shown that transfer RNA may offer a promising therapeutic avenue for treating genetic diseases.Fierce Biotech · 2d ago↗ source